Table 1.
Summary of patient clinicopathologic characteristics in thymoma
| Parameters | All patients (n = 194) | Superior (n = 27) | Inferior (n = 167) | P‐value |
|---|---|---|---|---|
| Age (years) (mean ± SD) (range) | 53.8 ± 14.5 (15–83) | 53.2 ± 13.5 (28–78) | 53.9 ± 14.7 (15–83) | 0.811a |
| Tumor diameter (cm) (mean ± SD) (rang) | 5.2 ± 2.5 (1.0–19.4) | 5.6 ± 3.1 (2.5–16.0) | 5.2 ± 2.4 (1.0–19.4) | 0.448a |
| Sex | 0.881b | |||
| Male | 98 (50.5%) | 14 (51.9%) | 84 (50.3%) | |
| Female | 96 (49.5%) | 13 (48.1%) | 83 (49.7%) | |
| MG | 0.007* , b | |||
| Yes | 64 (33.0%) | 15 (55.6%) | 49 (29.3%) | |
| No | 130 (67.0%) | 12 (44.4%) | 118 (70.7%) | |
| MGFA classification†,‡‡ | 0.492c | |||
| I | 28 (14.4%) | 8 (29.6%) | 20 (12.0%) | |
| II | 22 (11.3%) | 4 (14.8%) | 18 (10.8%) | |
| III | 5 (2.6%) | 1 (3.7%) | 4 (2.4%) | |
| IV | 5 (2.6%) | 2 (7.4%) | 3 (1.8%) | |
| V | 4 (2.1%) | 0 (0) | 4 (2.4%) | |
| Anti‐AchR¶ | 0.134b | |||
| Positive | 62 (32.0%) | 12 (44.4%) | 50 (29.9%) | |
| Negative | 132 (68.0%) | 15 (55.6%) | 117 (70.1%) | |
| WHO classification‡ | 0.069d | |||
| A | 17 (8.8%) | 2 (7.4%) | 15 (9.0%) | |
| AB | 45 (23.2%) | 4 (14.8%) | 41 (24.6%) | |
| B1 | 64 (33.0%) | 9 (33.3%) | 55 (32.9%) | |
| B2 | 50 (25.8%) | 5 (18.5%) | 45 (26.9%) | |
| B3 | 18 (9.3%) | 7 (25.9%) | 11 (6.6%) | |
| Masaoka‐Koga stage§ | 0.005* , c | |||
| I | 98 (50.5%) | 9 (33.3%) | 89 (53.3%) | |
| II | 54 (27.8%) | 7 (25.9%) | 47 (28.1%) | |
| III | 24 (12.4%) | 5 (18.5%) | 19 (11.4%) | |
| IV | 18 (9.3%) | 6 (22.2%) | 12 (7.2%) | |
| MPMT | 0.382e | |||
| Yes | 27 (13.9%) | 2 (7.4%) | 25 (15.0%) | |
| No | 167 (86.1%) | 25 (92.6%) | 142 (85.0%) | |
| Surgical radicality†† | 0.721e | |||
| R0 resection | 176 (90.7%) | 24 (88.9%) | 152 (91.0%) | |
| Non‐R0 resection | 18 (9.3%) | 3 (11.1%) | 15 (9.0%) | |
| Lymph node dissection | 0.881b | |||
| Yes | 41 (21.1%) | 6 (22.2%) | 35 (21.0%) | |
| No | 153 (78.9%) | 21 (77.8%) | 132 (79.0%) | |
| Lymph node metastasis§§ | 0.268e | |||
| Yes | 7 (3.6%) | 2 (33.3%) | 5 (14.3%) | |
| No | 34 (96.4%) | 4 (66.7%) | 30 (85.7%) | |
| Preoperative induction therapy | 0.114e | |||
| Yes | 9 (4.6%) | 3 (11.1%) | 6 (3.6%) | |
| No | 185 (95.4%) | 24 (88.9%) | 161 (96.4%) | |
| Postoperative adjuvant therapy | 0.998b | |||
| Yes | 79 (14.3%) | 11 (40.7%) | 68 (40.7%) | |
| No | 115 (85.7%) | 16 (59.3%) | 99 (59.3%) | |
| Disease progression | <0.001* , b | |||
| Yes | 26 (13.4%) | 12 (44.4%) | 14 (8.4%) | |
| No | 168 (86.6%) | 15 (55.6%) | 153 (91.6%) | |
| Recurrence¶¶ | <0.001* , b | |||
| Yes | 20 (11.4%) | 9 (37.5%) | 11 (7.2%) | |
| No | 156 (88.6%) | 15 (62.5%) | 141 (92.8%) |
P < 0.05.
Alfred Jaretzki et al. 2000.
Muller‐Hemelink et al. 1999.
Koga et al. 1994.
Positive: The serum titer of antiAchR ≥ 0.3 nmol/L. Negative: The serum titer of antiAchR<0.3 nmol/L (Nakajima et al. 2008).
R0 resection: no residual tumor on microscopy; Non‐R0 resection: microscopic or macroscopic residual tumor.
Only patients with MG were included (N = 64).
Only patients with lymph node dissection were included (N = 41).
Only patients with complete resection were included (N = 176).
Student's t‐test was used.
Chi‐square test.
Linear‐by‐linear association.
Likelihood ratio detection.
Fisher's exact test was used.
MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; anti‐AchR, anti‐acetylcholine receptor; WHO, World Health Organization; MPMT, multiple primary malignant tumors.